Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events

TA210 Vascular disease - clopidogrel and dipyridamole: review decision - September 2013 information

TA210 Vascular disease - clopidogrel and dipyridamole: GE decision paper September 2013 (PDF 124 KB)

TA210 Vascular disease - clopidogrel and dipyridamole: review proposal - July 2013 information

TA210 Vascular disease - clopidogrel and dipyridamole: Appendix A provisional matrix of stakeholders (PDF 103 KB)

TA210 Vascular disease - clopidogrel and dipyridamole: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 662 KB)

Press release: final guidance on clopidogrel and modified-release dipyridamole  information

2010/180 final guidance on clopidogrel and modified-release dipyridamole (PDF 79 KB)

Vascular disease - clopidogrel and dipyridamole (review): equality impact assessment (PDF 11 KB)

Vascular disease - clopidogrel and dipyridamole (review): press release information

2010/148 NICE publishes final draft guidance on clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (PDF 76 KB)

Vascular disease - clopidogrel and dipyridamole (review): final appraisal determination information

Vascular disease - clopidogrel and dipyridamole (review): final appraisal determination document (PDF 178 KB)

Vascular disease - clopidogrel and dipyridamole (review): response to consultee, commentator and public comments on the ACD (PDF 69 KB)

Vascular disease - clopidogrel and dipyridamole (review): consultee and commentator comments on the ACD

Vascular disease - clopidogrel and dipyridamole (review): professional and patient groups

Vascular disease - clopidogrel and dipyridamole (review): British Association of Stroke Physicians (PDF 20 KB)

Vascular disease - clopidogrel and dipyridamole (review): Diabetes UK and Association of British Clinical Diabetologists (joint response) (PDF 71 KB)

Vascular disease - clopidogrel and dipyridamole (review): Vascular Society (PDF 18 KB)

Vascular disease - clopidogrel and dipyridamole (review): Department of Health (PDF 15 KB)

Vascular disease - clopidogrel and dipyridamole (review): Clinical Specialist nominated by the British Cardiovascular Society (PDF 14 KB)

Vascular disease - clopidogrel and dipyridamole (review): Bristol-Myers Squibb and Sanofi-Aventis (joint response) (PDF 39 KB)

Vascular disease - clopidogrel and dipyridamole (review): appraisal consultation

Vascular disease - clopidogrel and dipyridamole (review): appraisal consultation document information

Vascular disease - clopidogrel and dipyridamole (review): overview (PDF 204 KB)

Vascular disease - clopidogrel and dipyridamole (review): assessment report

Vascular disease - clopidogrel and dipyridamole (review): assessment report (PDF 2.21 MB)

Vascular disease - clopidogrel and dipyridamole (review): assessment report addendum 1 (PDF 334 KB)

Vascular disease - clopidogrel and dipyridamole (review): assessment report addendum 2 (PDF 244 KB)

Vascular disease - clopidogrel and dipyridamole (review): assessment report addendum 3 (PDF 251 KB)

Vascular disease - clopidogrel and dipyridamole (review): assessment report addendum 4 (PDF 213 KB)

Vascular disease - clopidogrel and dipyridamole (review): consultee and commentator comments on the assessment

Vascular disease - clopidogrel and dipyridamole (review): Boehringer-Ingelheim (PDF 16 KB)

Vascular disease - clopidogrel and dipyridamole (review): British Association of Stroke Physicians (PDF 39 KB)

Vascular disease - clopidogrel and dipyridamole (review): Diabetes UK (PDF 27 KB)

Vascular disease - clopidogrel and dipyridamole (review): Sanofi-Aventis and Bristol Myers Squibb (joint response) (PDF 89 KB)

Vascular disease - clopidogrel and dipyridamole (review): Liverpool Reviews and Implementation Group (LRIG) (PDF 66 KB)

Vascular disease - clopidogrel and dipyridamole (review): non-manufacturer submissions

Vascular disease - clopidogrel and dipyridamole (review): Association of British Clinical Diabetologists and Diabetes UK (Joint Submission) (PDF 65 KB)

Vascular disease - clopidogrel and dipyridamole (review): Vascular Society (PDF 68 KB)

Vascular disease - clopidogrel and dipyridamole (review): manufacturer submissions (executive summary only)

Vascular disease - clopidogrel and dipyridamole (review): Boehringer-Ingelheim (PDF 14 KB)

Sanofi-Aventis and Bristol Myers Squibb (joint submission) (PDF 15 KB)

Vascular disease - clopidogrel and dipyridamole (review): expert written personal statements

Vascular disease - clopidogrel and dipyridamole (review): Geldard (PDF 12 KB)

Vascular disease - clopidogrel and dipyridamole (review): Robinson (PDF 35 KB)

Vascular disease - clopidogrel and dipyridamole (review): Ryckborst (PDF 13 KB)

Vascular disease - clopidogrel and dipyridamole (review): Smith (PDF 37 KB)

Vascular disease - clopidogrel and dipyridamole (review): full preceding guidance (PDF 413 KB)

Vascular disease - clopidogrel and dipyridamole (review): addendum to assessment report (PDF 334 KB)

Vascular disease - clopidogrel and dipyridamole (review): assessment report (PDF 2.25 MB)

Vascular disease - clopidogrel and dipyridamole (review): final protocol (PDF 176 KB)

Vascular disease - clopidogrel and dipyridamole: Institute's response to comments on the draft matrix (PDF 14 KB)

Vascular disease - clopidogrel and dipyridamole: Institute's response to comments on the draft scope (PDF 66 KB)

Vascular disease - clopidogrel and dipyridamole: final scope (PDF 31 KB)

Vascular disease - clopidogrel and dipyridamole: provisional matrix (PDF 35 KB)

Vascular disease - clopidogrel and dipyridamole: draft scope (PDF 34 KB)